Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
15 Results for "
SMARCA4 bromodomain
" in MedChemExpress (MCE) Product Catalog:
Products (15)
15 Results for "SMARCA4 bromodomain" in MCE Product Catalog:
Cat. No.: HY-40249
CAS No.: 286961-14-6
Target:
Research Areas:
GNE-064 (compound 5) is a selective, orally active and highly soluble inhibitor of SMARCA4, SMARCA2 and PBRM1 bromodomains 5. GNE-064 inhibits SMARCA4 with an IC50 of 0.035 μM and inhibits SMARCA2 with an EC50 of 0.10 μM. GNE-064 possess Kds with 0.01, 0.016, 0.018 and 0.049 μM for SMARCA4, SMARCA2, PBRM1 bromodomains 5 and PBRM1 bromodomains 2, repectively. GNE-064 can be used as a chemical probe for the research of agent synthesis .
Cat. No.: HY-170817
CAS No.: 3033592-13-8
Research Areas:
SMI-1074, a SMARCA bromodomain inhibitor, is a PROTAC target protein ligand (Ligand for Target Protein for PROTAC). SMI-1074 can be used for synthesis SMD-3236 (HY-170824) and SMD-1087 (HY-170828). SMI-1074 can be used for the research of smarca4-deficient cancers .
Cat. No.: HY-173333
CAS No.: 3081688-77-6
Target:
Research Areas:
PROTAC SMARCA2/4 degrader-38 is a SMARCA2/4 degrader (SMARCA2: DC50 = 3.0 nM; SMARCA4: 4.0 nM). PROTAC SMARCA2/4 degrader-38 binds to SMARCA2 and SMARCA4 bromodomains to induce degradation via the ubiquitin-proteasome system. PROTAC SMARCA2/4 degrader-38 induces G0/G1 phase cell cycle arrest and cell apoptosis in hematological cancer cells, blocks oncogenic activity of MYC and other disease-related genes in acute myeloid leukemia cells and inhibits proliferation of hematological cancer cell lines. PROTAC SMARCA2/4 degrader-38 can be used for the research of acute myeloid leukemia, diffuse large B-cell lymphoma, breast cancer, ovarian cancer, colorectal cancer, liver cancer, lung cancer .
Cat. No.: HY-144720
CAS No.: 2616813-99-9
Target:
Research Areas:
YH-IV-173 is a BRG1 (SMARCA4) bromodomain binder with higher affinity for BRG1 than for BRM. YH-IV-173 acts as a sensitizing agent when combined with Temozolomide (HY-17364), modulating glioblastoma (GBM) cell proliferation and tumor growth. YH-IV-173 treatment alone shows weak effects on glioblastoma cell growth and tumor growth .
Cat. No.: HY-171774
CAS No.: 1997321-76-2
Research Areas:
PBRM1/SMARCA2,4-ligand-1 (Compound 4) is a Ligand for Target Protein for PROTAC that binds to PBRM1, SMARCA2, and SMARCA4. PBRM1/SMARCA2,4-ligand-1 is a potent SMARCA4 bromodomain inhibitor. PBRM1/SMARCA2,4-ligand-1 can be used to synthesize PROTAC AU-24118 (HY-163410) .
Cat. No.: HY-122645
CAS No.: 1915012-19-9
Target:
Research Areas:
SMARCA2-IN-4 (Compound 26) is an inhibitor for SWI/SNF chromatin remodeling complexe SMARCA by targeting the bromodomains. SMARCA2-IN-4 exhibits high affinity for PB1(5), SMARCA2B and SMARCA4 with Kd of 124, 262 and 417 nM .
Cat. No.: HY-151531
CAS No.: 2819989-60-9
Research Areas:
PBRM1-BD2-IN-4 is a PBRM1-BD2 inhibitor with an IC50 of 0.2 μM, and its Kd values for PBRM1-BD2 and PBRM1-BD5 are 5.5 μM and 11.1 μM, respectively. PBRM1-BD2-IN-4 selectively inhibits the proliferation of PBRM1-dependent prostate cancer cells. PBRM1-BD2-IN-4 can be used in studies related to prostate cancer .
Cat. No.: HY-161882
CAS No.: 2669027-50-1
Target:
Research Areas:
PROTAC SMARCA2 degrader-8 is a SMARCA2 PROTAC degrader with a DC50 of 28 nM in A375 cells. PROTAC SMARCA2 degrader-8 forms a crystallizable ternary complex with the SMARCA4 bromodomain and VBC, promoting the ubiquitination and proteasomal degradation of SMARCA2. PROTAC SMARCA2 degrader-8 can be used in melanoma research .
Cat. No.: HY-122573
CAS No.: 1914047-59-8
Research Areas:
Bromodomain inhibitor-13 (Compound 1) is an analog of PFI-3 (HY-12409). Bromodomain inhibitor-13 is a bromodomain-containing protein (BCP) inhibitor. Bromodomain inhibitor-13 targets SMARCA2, SMARCA4, PB1(5), and second bromodomain of PB1 (PB1(2)) with KD values of 37, 53, 30, and 190 nM, respectively .
Cat. No.: HY-182987
Research Areas:
SMARCA2/SMARCA4 ligand-1 is a SMARCA2/SMARCA4 ligand with KD values of 1.2 and 10.3 nM. SMARCA2/SMARCA4 ligand-1 binds SMARCA2/4 bromodomain via hydrogen bonds with asparagine and tyrosine residues, and a salt bridge with a glutamate residue. SMARCA2/SMARCA4 ligand-1 shows antiproliferative activity against cancer cells. SMARCA2/SMARCA4 ligand-1 can be used for the research of cancer, such as smarca4 mutant nonsmall cell lung cancer .
Cat. No.: HY-162835
CAS No.: 2409844-88-6
Target:
Research Areas:
PROTAC SMARCA2/4 degrader-28 is a heterobifunctional PROTAC degrader targeting SMARCA2 and SMARCA4. PROTAC SMARCA2/4 degrader-28 forms a ternary complex with CRL2VHL E3 ligase and SMARCA2 or SMARCA4, mediating the ubiquitination and degradation of SMARCA2, while acting as a partial degrader of SMARCA4. PROTAC SMARCA2/4-degrader-28 can be used in cancer-related research .
Cat. No.: HY-170828
CAS No.: 3033586-04-5
Target:
Research Areas:
SMD-1087 is a VHL-recruiting SMARCA2 PROTAC degrader with a DC50 of 8 nM. SMD-1087 induces ubiquitination and degradation of SMARCA2 via the proteasome pathway. SMD-1087 reduces PBRM1 protein levels, inhibits the growth of SMARCA4-deficient cancer cells, and suppresses tumor growth in mouse xenograft models. SMD-1087 can be used for research on SMARCA4-deficient human cancers, including lung cancer and melanoma .
Cat. No.: HY-133908
CAS No.: 1914047-60-1
Target:
Research Areas:
PFI-3 Control is an inactive analog of PFI-3 (HY-12409), serving as an inactive negative control. PFI-3 Control shows no detectable binding activity toward purified PB1 (5), SMARCA2A, SMARCA2B, and SMARCA4 family VIII bromodomain proteins .
Cat. No.: HY-162834
CAS No.: 2375564-54-6
Target:
Research Areas:
PROTAC SMARCA2/4 degrader-27 is a VHL-recruiting PROTAC degrader targeting SMARCA2 and SMARCA4, derived from structure-guided modification of PROTAC SMARCA2/4 degrader-28 (HY-162835). PROTAC SMARCA2/4-degrader-27 forms a cooperative ternary complex with CRL2VHL E3 ligase to induce ubiquitination and degradation. PROTAC SMARCA2/4-degrader-27 induces a novel protein-protein interaction between VHL and SMARCA2/SMARCA4, thereby stabilizing ternary complex formation and promoting proteasomal degradation of target proteins. PROTAC SMARCA2/4-degrader-27 exhibits enhanced cell permeability and stronger ternary complex formation ability, leading to improved degradation activity. PROTAC SMARCA2/4-degrader-27 can be used in cancer-related research[1].
- 1
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
